Disc Medicine (IRON) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Voting matters and shareholder proposals
Election of three Class III nominees to the Board of Directors: Donald Nicholson, John Quisel, and William White, each recommended for election by the Board.
Advisory vote to approve compensation paid to named executive officers, with Board recommending approval.
Ratification of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, recommended by the Board.
Board of directors and corporate governance
Board recommends the election of three Class III director nominees at the annual meeting.
Executive compensation and say-on-pay
Advisory vote on executive compensation is included, with Board recommending approval.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Disc Medicine
- Proxy covers director elections, say-on-pay, auditor ratification, and performance-based compensation.IRON
Proxy filing29 Apr 2026 - Phase III data for bitopertin and key pipeline readouts are expected by year-end.IRON
Leerink Global Healthcare Conference 20269 Mar 2026 - Multiple late-stage programs advance toward pivotal data and regulatory milestones in 2024.IRON
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Advancing late-stage programs in hematology with strong clinical data and blockbuster market potential.IRON
Corporate presentation3 Mar 2026 - Strong cash reserves and advancing clinical programs position the company for key 2026 milestones.IRON
Q4 202526 Feb 2026 - FDA CRL requires APOLLO results for bitopertin; decision expected by mid-2027.IRON
Status update17 Feb 2026 - Bitopertin and DISC-0974 advance toward pivotal trials, with strong efficacy and financial runway.IRON
Stifel 2024 Healthcare Conference3 Feb 2026 - Advancing late-stage therapies for rare and common anemias, with key regulatory and clinical catalysts ahead.IRON
TD Cowen 45th Annual Healthcare Conference3 Feb 2026 - Robust Phase 2 results across three programs set the stage for pivotal trials and key data in 2024–2025.IRON
2024 European Hematology Association Congress3 Feb 2026